Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Pharma/Biotech
Recent news which mentions Pharma/Biotech
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
2 Top Biotech Buyout Candidates
March 31, 2024
Tickers
IBB
LLY
MDGL
NVO
Tags
Pharma/Biotech
Stocks / Equities
Market News
From
TalkMarkets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
March 30, 2024
Tickers
ATAI
CMPS
GHRS
IXHL
Tags
Pharma/Biotech
Stocks / Equities
Market News
From
TalkMarkets
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
March 30, 2024
Tickers
AVBP
BGNE
NUVB
SPHDF
Tags
Stocks / Equities
Pharma/Biotech
Market News
From
TalkMarkets
These DAX Index Stocks Surged In The First Quarter
March 28, 2024
Tickers
DAX
Tags
Energy
Transportation
Capital & Industrial Goods
From
TalkMarkets
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
Tickers
ABBV
ADM
BIIB
CERE
Tags
ETFs
Market News
Healthcare
From
TalkMarkets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Tickers
BGNE
CTLT
IVBXF
MRK
Tags
Stocks / Equities
Pharma/Biotech
Market News
From
TalkMarkets
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024
Tickers
ABBV
GLYC
Tags
Market News
Stocks / Equities
Pharma/Biotech
From
TalkMarkets
Healthcare And Biotech Update With Market At 2024 Highs
March 20, 2024
Tickers
ABBV
IBB
LLY
NVDA
Tags
Healthcare
Market News
Stocks / Equities
From
TalkMarkets
CSL Ltd. (ASX) Elliott Wave Technical Analysis - March 18, 2024
March 18, 2024
Tickers
ASX
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
March 16, 2024
Tickers
ASLN
HNSPF
REGMF
SOLTF
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
The Generic Drugs Antitrust Case
March 16, 2024
Tickers
TEVA
Tags
Market News
Stocks / Equities
Pharma/Biotech
From
TalkMarkets
In a Free Market, Drugs Are Cheap, Government Policies Make Them Expensive
March 12, 2024
Tags
Market News
Healthcare
Pharma/Biotech
From
TalkMarkets
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
March 11, 2024
Tickers
ATAI
CMPS
GHRS
IXHL
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
March 11, 2024
Tickers
CRBU
CRSP
HOLX
QDEL
Tags
Pharma/Biotech
Stocks / Equities
ETFs
From
TalkMarkets
Current Analysis: Elekta AB (EKTAF)
March 10, 2024
Tickers
EKTAF
Tags
Pharma/Biotech
Stocks / Equities
Healthcare
From
TalkMarkets
What A Trip: Psychedelic Medicine Company MindMed Shares Rocket 50% After Positive Data
March 10, 2024
Tickers
MNMD
Tags
Stocks / Equities
Pharma/Biotech
Market News
From
TalkMarkets
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Tickers
ASND
EXAS
EXEL
LEGN
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
March 09, 2024
Tickers
AKESF
AVGR
IVBXF
Tags
Stocks / Equities
Pharma/Biotech
Market News
From
TalkMarkets
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
Tickers
ALNY
AZN
JNJ
MRK
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
NuGen Medical’s Needle-Free Injection Could Be Game-Changer
March 07, 2024
Tickers
NGMDF
Tags
Market News
Healthcare
Pharma/Biotech
From
TalkMarkets
Landos Biopharma - Investor Like It Better Than Analysts
March 07, 2024
Tickers
LABP
Tags
Pharma/Biotech
Stocks / Equities
Market News
From
TalkMarkets
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Tickers
ABCL
ABSI
BTAI
EXAI
Tags
Market News
Technology
Stocks / Equities
From
TalkMarkets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Tickers
AZN
FGEN
IRON
IVBXF
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
Tickers
ATAI
CMPS
GHRS
IXHL
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Coya Therapeutics
February 29, 2024
Tickers
COYA
Tags
Market News
Stocks / Equities
Pharma/Biotech
From
TalkMarkets
ADC Therapeutics - Time For A Turn-Around?
February 27, 2024
Tickers
ADCT
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Vertex Pharmaceuticals (VRTX) Should Remain Supported
February 27, 2024
Tickers
VRTX
Tags
Market News
Stocks / Equities
Pharma/Biotech
From
TalkMarkets
Lottery Preference And Biotech Stocks: Trust The Financials, Not The Science
February 25, 2024
Tickers
IBB
Tags
Market News
Pharma/Biotech
Stocks / Equities
From
TalkMarkets
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Tickers
GILD
IVBXF
JBPHF
LEGN
Tags
Market News
Stocks / Equities
Pharma/Biotech
From
TalkMarkets
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
Tickers
ALPMY
BAYRY
GERN
IOVA
Tags
Pharma/Biotech
Stocks / Equities
Market News
From
TalkMarkets
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.